Drug Search Results
More Filters [+]

Chlorprothixene

Alternative Names: chlorprothixene, taractan
Latest Update: 2019-02-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DR Antagonist,ADR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bulgaria | Czech | Denmark | Estonia | Finland | Hungary | Iceland | India | Ireland | Italy | Korea | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Russia | Saudi Arabia | Slovakia | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: University Medical Center Groningen
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Chlorprothixene

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Schizophrenia

Phase 3: Schizophrenia|Tic Disorders|Dementia|Depressive Disorder|Psychophysiologic Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAILOR

P4

Terminated

Schizophrenia

2027-03-03

BAR-MEDS Chlorprothixene

N/A

Recruiting

Obesity, Morbid

2026-12-01

HAMLETT

P4

Active, not recruiting

Schizophrenia

2021-02-04

GAP

P3

Terminated

Depressive Disorder|Dementia|Psychophysiologic Disorders|Tic Disorders|Schizophrenia

2017-06-28

Recent News Events

Date

Type

Title